. All brand names or trademarks appearing in this report are the property of their respective owners. Unless the context requires otherwise, references in this report to AN2, we, our, the Company or the Registrant refer to AN2 Therapeutics. Overview We are a clinical stage biopharmaceutical company focused on the discovery and development of novel small-molecule therapeutics derived from our boron chemistry platform. Our development pipeline spans hematologic diseases, infectious diseases, and o...
Q2 FY2026 — expected 2026-08-12
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2026-03-17 | 2025-12-31 | 0001193125-26-110693 | EDGAR | 79K words |
| 2025-03-25 | 2024-12-31 | 0000950170-25-044366 | EDGAR | — |
| 2024-03-29 | 2023-12-31 | 0000950170-24-038681 | EDGAR | — |
| 2023-03-29 | 2022-12-31 | 0000950170-23-010627 | EDGAR | — |
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2025-11-12 | 2025-09-30 | 0001193125-25-277673 | EDGAR | 60K words |
| 2025-08-12 | 2025-06-30 | 0000950170-25-107301 | EDGAR | — |
| 2025-05-13 | 2025-03-31 | 0000950170-25-070358 | EDGAR | — |
| 2024-11-13 | 2024-09-30 | 0000950170-24-126282 | EDGAR | — |
| 2024-08-13 | 2024-06-30 | 0000950170-24-096243 | EDGAR | — |
| 2024-05-14 | 2024-03-31 | 0000950170-24-059556 | EDGAR | — |
| 2023-11-09 | 2023-09-30 | 0000950170-23-062081 | EDGAR | — |
| 2023-08-10 | 2023-06-30 | 0000950170-23-041378 | EDGAR | — |
| 2023-05-11 | 2023-03-31 | 0000950170-23-021291 | EDGAR | — |
| 2022-11-09 | 2022-09-30 | 0000950170-22-023901 | EDGAR | — |
| 2022-08-11 | 2022-06-30 | 0000950170-22-016900 | EDGAR | — |
| 2022-05-10 | 2022-03-31 | 0000950170-22-008999 | EDGAR | — |
| Filed | Accession | Source | Full Text |
|---|---|---|---|
| 2026-03-20 | 0001193125-26-117765 | EDGAR | 1K words |
| 2026-03-17 | 0001193125-26-110681 | EDGAR | — |
| 2026-03-10 | 0001193125-26-099169 | EDGAR | — |
| 2026-01-29 | 0001193125-26-029540 | EDGAR | — |
| 2025-11-12 | 0001193125-25-277662 | EDGAR | — |
| 2025-08-12 | 0000950170-25-107278 | EDGAR | — |
| 2025-06-20 | 0001193125-25-143187 | EDGAR | — |
| 2025-06-11 | 0001193125-25-138796 | EDGAR | — |
| 2025-05-27 | 0001193125-25-127595 | EDGAR | — |
| 2025-05-13 | 0000950170-25-070305 | EDGAR | — |
60 total filings indexed. 34 additional filings (S-1, DEF 14A, etc.) View all (JSON) · SEC EDGAR
| CIK | 0001880438 |
| Ticker | ANTX |
| Exchange | Nasdaq |
| SIC | 2834: Pharmaceutical Preparations |
| Incorporated | DE |
| Website | https://www.an2therapeutics.com |
| Listed | 2022-03-25 |
This is the free public profile. For structured JSON with full provenance chain, use the API:
JSON Profile Stock Quote AI Readiness Report